• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Clinical Data's Cogenics Division Completes Installation of Illumina iScan System

Posted on: Thursday, 29 May 2008, 06:00 CDT

Clinical Data, Inc. (NASDAQ:CLDA) announced today that its Cogenics(R) division, a leading provider of value-based genomic solutions to the healthcare and life sciences industries, has validated installation of the Illumina iScan System in its Morrisville, North Carolina site. Illumina is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Its iScan System includes a high-resolution scanner that supports rapid, sensitive, and accurate imaging of Illumina's BeadChip-based genetic analysis products. Cogenics is the first commercial genetic services provider to install the iScan System within Illumina's early access program and plans to use the system to further strengthen its leading portfolio of genomic services and solutions.

During its validation of the iScan System, Cogenics was able to process the Human610-Quad chip six times faster than was possible with the previous BeadStation platform. This positions Cogenics as the highest capacity commercial service provider worldwide. Customers can run multiple custom genotyping applications, and choose between 6,000 and 60,000 markers for custom assays.

"The iScan System enhances Cogenics' leadership position in the genomic services arena by adding more value-based solutions for industry and academic customers that have adopted Illumina BeadChip-based genotyping and gene expression products as their preferred platform," said Clive Higgins, Cogenics' General Manager, North America. "We plan to leverage the iScan System's capabilities first in the area of discovery and clinical genotyping, copy number variation, whole genome association studies, whole genome transcription profiling and DNA methylation, a significant extension of our broad array of current service offerings."

In addition to installing the iScan System, Cogenics is also pursuing Illumina CSPro certification for its BeadChip-based genotyping and gene expression analysis applications.

For more information about Cogenics and its genomic services offerings, please call 1-877-226-4364 or email sales@cogenics.com.

About Cogenics

Cogenics, a division of Clinical Data, offers nearly 20 years of experience as a leading provider of value-based genomic solutions to the Healthcare and Life Sciences industries. Cogenics combines quality operations from the acquisitions of Genaissance Pharmaceuticals, Lark Technologies (US and UK), Icoria, Genome Express (France), and Epidauros Biotechnologie AG (Germany), and its portfolio of service offerings presently includes genotyping, sequencing, gene expression, biomanufacturing support and sample extraction, management and biobanking for both research and regulated environments, including GLP, cGMP and CLIA. Cogenics' customers include some of the world's most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies. For more information, please visit www.cogenics.com.

About Clinical Data, Inc.

Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare(TM). Its PGxHealth(R) division focuses on proprietary biomarker and pharmacogenetic test development as well as targeted therapeutics to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics(R) division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the company's website at www.clda.com for more information.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such information and statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Cogenics' services will gain wide acceptance in the market; competition from pharmaceutical, biotechnology and diagnostics companies; whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; changes in government regulations, and changing relationships with customers, payers, suppliers and strategic partners; and those risks identified and discussed by Clinical Data in its filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC periodic and interim reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2007, Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2007, and Current Reports on Form 8-K filed from time to time by the Company.

Source: Business Wire

More News in this Category